Frost & Sullivan releases an independent market study report on the skin, kidney disease and rheumatic drug markets

Recently, the globally renowned growth consulting firm Frost & Sullivan released an 'Independent Market Study on the Skin and Nephropathy and Rheumatic Drugs Markets'. The report provides a detailed analysis of the market overview, driving factors, and future development trends of the skin and rheumatic drugs industry in China. It focuses on sorting out an overview of skin diseases in China, the current treatment status; as well as an overview of autoimmune diseases in China and their current treatment status. Compared to other areas of medicine, skin disease drugs typically have lower unit prices but higher profit margins, and are relatively less affected by policies in the market. Therefore, with the improvement of people's consumption capacity and enhanced health awareness, the skin disease drugs market will continue to expand. In the field of autoimmune diseases (rheumatic), tripterygium extract is particularly known for its potent anti-inflammatory effects and is considered a potential drug for treating multiple sclerosis and other autoimmune or inflammatory diseases.